scm logo

Our graft versus host disease (GVHD) fresh homogeneous stem cell therapy has been approved by the Ministry of Food and Drug Safety for phase 2 clinical trials. 

GVHD is a complication caused by rejection through immune system stimulation during homogeneous bone marrow transplantation and is classified into acute and chronic types according to the timing of occurrence and is an intractable disease without effective cure in the event of primary treatment failure.

Globally, GVHD is the world's largest number of single diseases are clinical trials. And The GVHD stem cell therapy market is a market with an average annual growth rate of 6.6% from $300 million in 2013 to $400 million in 2018 and is highly commercial when the treatment development is successful.

Through the phase 2 clinical trial approved this time, the company proved the effectiveness and safety of the treatment for graft versus host disease.

In order to treat refractory diseases such as GVHD, we have secured high purity stem cell separation source technology, customized treatment development, and mass production technology.

The company holds patents from South Korea, the United States, Japan, China, and the European Union (EU) for its "(SCM, Subfraction Culturing Method)" and high-purity stem cell treatment manufacturing technology that can separate high-purity adult stem cells (cMSCs).

The "“Subfractionation Culturing Method”" developed by the company after long research is a technology that separates high-purity stem cells that are much purer than the existing stem cell separation method, "agricultural drainage centrifugation method."

Song Sun-uk, CEO of our company, said, “As we have the original technology to maximize the efficacy while maintaining the safety of the treatment, we will start the phase 2 clinical trial in April and do our best to commercialize it as a treatment for rare and incurable diseases.” And "I want to provide hope to patients with refractory diseases who do not have a suitable treatment," he said.

Meanwhile, we have secured original technologies, patents, and manufacturing facilities for stem cell therapy for intractable diseases.

On the 12th, it succeeded in attracting a total of 10 billion won in additional funds from domestic venture capital and is considered a company with advanced technology that can open a new chapter in stem cell treatment and is preparing for listing.